Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 6/20 | 0.64 |
| ▸ | KDM4A | O75164 | 2/20 | 0.64 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.64 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.64 |
| ▸ | TET3 | O43151 | 2/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29564072 | 1.00 | TET2 (0.64) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL10195874 | 1.00 | TET2 (0.64) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL1487622 | 0.83 | GPR84 (0.59) | TET2KDM4AKDM4CKDM2ATET3 | |
| Urea SCHEMBL29093486 | 0.82 | TET2 (0.85) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL403629 | 0.81 | ALOX15 (0.48) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL465914 | 0.78 | TET2 (1.00) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL7509 | 0.78 | TET2 (1.00) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL864236 | 0.78 | TET2 (1.00) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL31620639 | 0.78 | TET2 (1.00) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL8032 | 0.78 | TET2 (1.00) | TET2KDM4AKDM4CKDM2ATET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105254687-A | Synthetic method of environment-friendly amikacin | QILU TIANHE PHARMACEUTICAL CO LTD | 2016-01-20 | — | — | CN | claimed |
| CN-1066842-A | The alpha-hydroxy-r-amino-butyric acid synthesis technique | CHENGDU PHARMACEUTICAL FACTORY (CN) | 1992-12-09 | — | — | CN | claimed |
| US-4363815-A | Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions | YU RUEY J | 1982-12-14 | — | — | US | claimed |
| CN-107299072-B | Engineering bacterium and application thereof | 江南大学 | 2020-11-06 | — | — | CN | disclosed |
| US-20190029941-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | Dermaforce Holdings, LLC | 2019-01-31 | — | — | US | disclosed |
| US-10123960-B2 | Methods for treating of skin conditions with retinoid double conjugate compounds | PCR TECHNOLOGY HOLDINGS, LC (US) | 2018-11-13 | — | — | US | disclosed |
| CN-105254687-B | A kind of synthetic method of amikacin | 齐鲁天和惠世制药有限公司 | 2018-06-19 | — | — | CN | disclosed |
| CN-107299072-A | Engineering bacterium and application thereof | 江南大学 | 2017-10-27 | — | — | CN | disclosed |
| US-20170129870-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | ALAPATI MOHAN MURALI (IN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129870-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | ALAPATI MOHAN MURALI (IN) | 2017-05-11 | — | — | US | disclosed |
| CN-106397232-A | Synthetic method for methoxy kanamycin drug intermediate gamma-amino-alpha-hydroxybutyric acid | 厦门市凯尔利信息科技有限公司 | 2017-02-15 | — | — | CN | disclosed |
| US-8883720-B2 | Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity | POLYPHOR AG (CH) | 2014-11-11 | — | — | US | disclosed |
| EP-2614042-A1 | PROCESS FOR THE DIRECT AMINATION OF SECONDARY ALCOHOLS WITH AMMONIA TO GIVE PRIMARY AMINES | Evonik Degussa GmbH (DE) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165672-A1 | PROCESS FOR THE DIRECT AMINATION OF SECONDARY ALCOHOLS WITH AMMONIA TO GIVE PRIMARY AMINES | EVONIK DEGUSSA GMBH (DE) | 2013-06-27 | — | — | US | disclosed |
| CN-103097324-A | Process for the direct amination of secondary alcohols with ammonia to give primary amines | EVONIK DEGUSSA GMBH | 2013-05-08 | — | — | CN | disclosed |
| WO-2012031884-A1 | PROCESS FOR THE DIRECT AMINATION OF SECONDARY ALCOHOLS WITH AMMONIA TO GIVE PRIMARY AMINES | EVONIK DEGUSSA GMBH (DE) | 2012-03-15 | — | — | WO | disclosed |
| US-20110312879-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR AG (CH) | 2011-12-22 | — | — | US | disclosed |
| WO-2010060479-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR AG (CH) | 2010-06-03 | — | — | WO | disclosed |
| EP-0430234-A2 | Process for the production of omega-amino-alpha-hydroxycarboxylic acid | Kanegafuchi Chemical Industry Co., Ltd. (JP) | 1991-06-05 | — | — | EP | disclosed |
| US-4363815-A | Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions | YU RUEY J | 1982-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123960-B2 | Methods for treating of skin conditions with retinoid double conjugate compounds | RARA, LRAT, RARG | TET2 3046/4885KDM4A 2646/4885KDM4C 2518/4885 |
| US-20110312879-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH CXCR4 ANTAGONIZING ACTIVITY | CXCL12, CXCR4, CXCR1 | TET2 4292/4885KDM4A 4267/4885KDM4C 4118/4885 |
| US-20170129870-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | SLC5A1, SLC6A4, SLC6A2 | TET2 2272/4885KDM4A 2621/4885KDM4C 2438/4885 |
| US-20130165672-A1 | PROCESS FOR THE DIRECT AMINATION OF SECONDARY ALCOHOLS WITH AMMONIA TO GIVE PRIMARY AMINES | ADH1C, ADH5, ADH1A | TET2 80/4885KDM4A 1616/4885KDM4C 857/4885 |
| US-20190029941-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | RARA, RARG, RXRA | TET2 3782/4885KDM4A 3983/4885KDM4C 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.